• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Neurocognitive deficits in congenital heart disease may not worsen with age

bySara RubinandLeah Carr, MD
May 31, 2016
in Cardiology, Neurology, Pediatrics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Although children with congenital heart disease (CHD) performed worse than matched controls on intelligence assessments at ages 4 and 7, relative improvement was observed at age 7.

2. Motor coordination, working memory, inhibition, and cognitive flexibility were not significantly different between children with CHD and matched controls at the examined time points.

Evidence Rating Level: 3 (Fair)

Study Rundown: As medical techniques for treating CHD have advanced, more children are surviving into adulthood. Due partly to their underlying genetic defect, surgery in infancy, and environmental influences, children with CHD are at greater risk of having neurocognitive deficits than those who do not have CHD. Previous work has suggested that neurocognitive functioning in children with CHD may decline with age due to increasing cognitive demands, a phenomenon known as “growing into deficit” (GID), but longitudinal data with matched healthy controls has been scarce. To investigate whether children with CHD would exhibit worsening function compared to age-matched controls, the GID study assessed neurocognitive function in a subset of children who had enrolled as infants in the Leuven glucose control trial (LGC-trial). Children with CHD performed significantly worse on intelligence quotient (IQ) tests at ages 4 and 7 but showed relative improvement at the second time point. Alertness, while significantly worse at age 4, was comparable to that of controls at age 7. Motor coordination, inhibition, and cognitive flexibility were not significantly different between groups at the studied time points. Though limited by its lack of an objective imaging correlate (e.g., magnetic resonance imaging (MRI)) and inability to assess the impact of prior enrollment and treatment in the LGC-trial, the finding of persistent neurocognitive deficits at age 7 in children with CHD coupled to evidence of catch-up on some metrics, warrants continued clinical monitoring and further investigation into possible interventions to further narrow the gap.

Click to read the study, published today in Pediatrics

Relevant Reading: Neurodevelopmental outcomes in children with congenital heart disease: evaluation and management

In-Depth [case-control study]: Participants in the GID study included 100, 7-year olds with CHD and 72 healthy matched controls. The children with CHD were a subset of individuals in the LGC-trial, identified in the pediatric intensive care unit of the University Hospitals Leuven, Belgium following heart surgery. At ages 4 and 7, general intellectual functioning was measured by the Dutch version of the Revised Wechsler Preschool and Primary Scale of Intelligence (WPPSI-R), visual-motor integration (VMI) was assessed by the Beery-Buktenica Developmental Test of Visual-Motor Integration, and attention, motor coordination, and executive functions were tested by 4 computerized tasks of the Amsterdam Neuropsychological Tasks. Psychosocial functioning was assessed (Child Behavior Checklist (CBCL)), as well. The significance of group (CHD vs. control), time (age 4 vs. age 7), and the change over time in each group were examined, with the hypothesis that greater neurocognitive deficit would be observed with increasing age. Although total IQ score remained lower at age 7 in the CHD group compared to children without CHD, the gap separating the groups diminished from 11.7 IQ points at age 4 to 7 points difference at age 7 (interaction p = 0.003). VMI was significantly worse in the CHD group (p < 0.001), and there was no improvement seen in this skillset by age 7 (interaction p = 0.207). Psychosocial function across all measures appeared to be worse at age 7 compared to age 4 in both children with CHD and healthy controls (although different age-appropriate checklists were used); however, only the CBCL-total problems metric was significantly worse in the CHD group compared to controls (p = 0.013)—CBCL-internalizing and CBCL-externalizing problems trended toward significance.

RELATED REPORTS

Impairment in executive function associated with congenital heart disease in school-aged children

Prematurity linked to increased risk of heart failure in adulthood

Early developmental screening of children with single ventricle physiology may not identify future deficits

Image: PD

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: congenital heart disease (CHD)neurocognition
Previous Post

Antihypertensives not linked to decreased cardiovascular events: The HOPE-3 trial

Next Post

Hospital mobility program linked to preserved mobility following in-patient admission

RelatedReports

Cardiology

Impairment in executive function associated with congenital heart disease in school-aged children

October 6, 2021
Rilonacept may lower pericarditis recurrence in patients with relapsing pericarditis
2 Minute Medicine

Prematurity linked to increased risk of heart failure in adulthood

April 12, 2021
Cardiology

Early developmental screening of children with single ventricle physiology may not identify future deficits

January 13, 2021
β-2 agonist exposure in utero linked to autism
Cardiology

Congenital heart disease associated with autism spectrum disorder diagnosis

October 27, 2019
Next Post
HOSPITAL score predicts risk of 30-day potentially avoidable readmission to hospital

Hospital mobility program linked to preserved mobility following in-patient admission

Selexipag may decrease mortality related to pulmonary arterial hypertension: The GRIPHON study

2 Minute Medicine Rewind May 30, 2016

Normal renal ultrasound only rules out high grade vesicoureteral reflux in infants

Catheter-associated UTI prevention program decreases UTI rates in hospital settings

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Bimekizumab shows a favourable 2-year safety profile in patients with moderate to severe plaque psoriasis
  • Medical cannabis provides little improvement to sleep in chronic pain patients
  • Alzheimer disease in individuals with Down syndrome has similar variability in age of onset and mortality rate as autosomal dominant forms
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.